• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Psoriatic arthritis (PsA) - Articles and news items

committee-recommends-arthritis-drug

NICE recommends Apremilast for treating psoriatic arthritis

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

The committee felt the addition of apremilast to the existing treatments would give patients access to a treatment with a different mechanism of action…

biosimilar-disease-drug

FDA approves Novartis’ biosimilar to treat multiple inflammatory diseases

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis…

sb5

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

bimekizumab

Bimekizumab demonstrates positive results in patients with psoriatic arthritis

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated…

cosentyx

Novartis plans head-to-head studies of Cosentyx versus Humira

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

tofacitinib

Positive top-line results for tofacitinib citrate in active psoriatic arthritis

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The OPAL Beyond study met its primary efficacy endpoints demonstrating a statistically significant improvement with tofacitinib 5 mg BID and 10 mg BID…

flixabi

Infliximab biosimilar Flixabi approved in the EU

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade…

Golimumab

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

cosentyx

FDA approves Novartis’ Cosentyx for AS and PsA

Industry news / 18 January 2016 / Victoria White

Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)…

zzz

Lilly’s ixekizumab demonstrates efficacy in psoriatic arthritis

Industry news / 10 November 2015 / Victoria White

Psoriatic arthritis patients treated with ixekizumab for 24 weeks achieved significant improvements in signs and symptoms of their disease compared to placebo…

cosentyx-2

CHMP recommends approval of Cosentyx for ankylosing spondylitis and psoriatic arthritis

Industry news / 23 October 2015 / Victoria White

Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

novartis-Secukinumab

Secukinumab demonstrates efficacy in psoriatic arthritis

Industry news / 1 October 2015 / Victoria White

Secukinumab is the first interleukin-17A inhibitor to demonstrate efficacy in a Phase III study in patients with active psoriatic arthritis…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +